Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates
Pavlo Gilchuk(AstraZeneca (Japan)), James E. Crowe(Vanderbilt University Medical Center), Kevin J. Whaley(Mapp Biopharmaceutical (United States)), Michael Pauly(Mapp Biopharmaceutical (United States)), Robert W. Cross(The University of Texas Medical Branch at Galveston), James C. Slaughter(Vanderbilt University Medical Center), Larry Zeitlin(Mapp Biopharmaceutical (United States)), Chad E. Mire(United States Department of Agriculture), Thomas W. Geisbert(The University of Texas Medical Branch at Galveston), Jeremy Mani(Vanderbilt University Medical Center), Andrew I. Flyak(Vanderbilt University), Daniel J. Deer(The University of Texas Medical Branch at Galveston), Jesús Velasco(Mapp Biopharmaceutical (United States)), Joan B. Geisbert(The University of Texas Medical Branch at Galveston), Krystle N. Agans(Galveston College)
Cited by 27
Related Papers
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
|Cell Host & Microbe|2020|1.2k
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
|Nature Medicine|2021|1k
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
|Nature Medicine|2020|543
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates
|Science Translational Medicine|2021|503